Review
Nature Reviews Cancer 6, 130-140 (February 2006) | doi:10.1038/nrc1801
Focus on: Biomarkers
Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics
Cornelia M. Ulrich1, Jeannette Bigler1 & John D. Potter1 About the authors
Abstract
Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) show indisputable promise as chemopreventive agents. Possible targets include cancers of the colon, stomach, breast and lung. However, recent studies raise concern about potential cardiovascular toxicity associated with the use of NSAIDs that specifically target the enzyme cyclooxygenase 2. These findings, and others that show that inherited genetic characteristics might determine preventive success, argue for new strategies that are tailored to individual medical history and genetic make-up.
- View At a Glance
Author affiliations
- Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, Washington 98109, USA.
Correspondence to: Cornelia M. Ulrich1 Email: nulrich@fhcrc.org
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
COX-2 inhibitors for colorectal cancerNature Medicine News and Views (01 Apr 1998)
Combinations for cancer preventionNature Medicine News and Views (01 Sep 2000)
See all 4 matches for News And ViewsRESEARCH
Determination of an optimal dosing regimen for aspirin chemoprevention of 1,2-dimethylhydrazine-induced colon tumours in ratsBritish Journal of Cancer Scientific Correspondence
See all 18 matches for Research